Professional Documents
Culture Documents
4 March, 2012
Approx 425 out of 465 bulk drugs used, are manufactured in India
Sale of all types of medicines in the country is expected to reach around US$19.22 billion by 2012.
January December 2011 RANK MANUFACTURERS 12M. 12M.% TOTAL MARKET 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 53,802.84 100 5.06 3.95 3.82 3.77 3.37 2.95 2.77 2.69 2.51 2.41 2.38 2.16 2.09 2.03 2.00 1.87 1.82 1.75 1.71 1.64 1.63 1.62 1.52 1.46 1.32 14.9 11.7 9.1 12.7 22.8 22.7 17.7 29.0 13.7 42.6 28.0 11.9 18.6 15.3 8.1 15.6 7.0 24.2 11.7 15.4 14.5 22.1 22.2 14.6 1.1 4.7 Values In M.S. Growth Crores % +/-%
CIPLA 2,722.60 GLAXOSMITHKLINE 2,125.35 ABBOTT HEALTHCARE2,053.03 SUN PHARMA 2,030.83 MANKIND 1,815.27 19.97 ALKEM 1,588.19 ABBOTT 1,491.28 LUPIN LIMITED 1,448.62 MACLEODS PHARMA 1,349.95 INTAS 1,294.56 33.31 ZYDUS CADILA 1,280.25 RANBAXY 1,163.77 SANOFI 1,123.17 DR REDDYS LABS 1,091.26 TORRENT PHARMA 1,078.50 43.97 ARISTO PHARMA 1,006.39 USV 978.76 ALEMBIC 942.52 MICRO LABS 917.72 PFIZER 880.23 52.75 GLENMARK PHARMA 874.53 WOCKHARDT 871.75 NOVARTIS 815.39 FDC 784.07 IPCA LABS 707.84
60.29
January December 2011 RANK MANUFACTURERS 12M. 12M.% 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 EMCURE ELDER PHARMA GERMAN REMEDIES UNICHEM WYETH LIMITED ZUVENTUS PHARMA CADILA PHARMA MERCK LIMITED FRANCO INDIAN STANCARE 69.63 HIMALAYA DRUG RANBAXY GLOBAL CHC ASTRA ZENECA INDOCO SOLVAY PHARMA 72.94 REXCEL BLUE CROSS UNIQUE PHARM MEDLEY PHARMA UNISEARCH 75.52 RAPTAKOS BRETT WIN MEDICARE BIOCHEM WALLACE JANSSEN 77.75 661.61 589.11 559.45 484.78 473.30 465.44 462.85 460.77 454.33 416.58 398.16 391.06 341.56 336.74 310.21 309.67 306.86 265.74 257.63 252.68 250.85 248.73 247.96 232.90 223.27 1.23 1.09 1.04 0.90 0.88 0.87 0.86 0.86 0.84 0.77 0.74 0.73 0.63 0.63 0.58 0.58 0.57 0.49 0.48 0.47 0.47 0.46 0.46 0.43 0.41 11.6 17.8 9.0 6.2 24.6 29.4 13.3 10.5 8.4 6.7 8.4 33.7 23.9 1.3 28.1 10.2 17.0 16.2 12.5 2.4 15.0 12.8 7.0 10.5 16.3 Values In Crores M.S. % Growth +/-%
Total Pharma
53,803
100.00
+15
Phase I Early Years Market share domination by foreign companies Absence of Indian companies
1970
1980
PhaseII Government Control Indian Patent Act 1970 Drug prices capped Local companies begin to make an impact
1990 Production
2000
Phase IV Growth Phase Rapid expansion of domestic market International market development Research Orientation
2010
Growth about 14 to 15% Growth driven by the growing number of patients gaining access to affordable medicines Regulatory process being upgraded New policy being discussed to let market driven prices prevail Low resources and investments for innovation in R&D India advantage being extended to Global players for cost containment in R&D and production. India having potential to become Global hub for Pharma market worldwide Highest no. of USFDA approved facilities outside the US
Meanwhile, Indian firms have chosen to take their existing product portfolios and target semi-urban and rural populations eg. Mankind, Alkem, Aristo, Nicholas Piramal.
Now MNCs like Sanofi, Novartis, Aventis, GSK and Pfizer are also exploring semi-urban rural markets.
EMs contributed almost half of global growth in the past few years (despite a 20 per cent market share) and this contribution is projected to increase to 70 per cent in the next five years.
In 2008, one inbound deal took place, where Ranbaxy was bought over by Daiichi Sankyo for $4 billion. In 2009, about five inbound deals took place. Sanofi-Aventis bought Shantha for $625 million, Hospira Inc acquired Orchid for $400 million Mylan acquired Matrix for $133 million Pfizer Animal Health's bought Ventex AFCL from ICICI Venture for $75 million and Ventoquinol's acquired Wockhardt's animal health business for $31 million In 2010, apart from $3.7-billion Abbott-Piramal deal, the only single deal in pure pharma space was that of US-based Avantor's buyout of RFCL from ICICI Venture for $112 million. In 2011, Reckitt Benckiser acquired Paras Pharma for US$ 726 mio.
Healthcare Ltd.
Similarly, US-based Merck joined hands with Sun Pharma, eyeing emerging markets.
In 2010, Anglo-Swedish drug maker AstraZeneca signed its first branded generics supply deal, with Torrent Pharmaceuticals.
In 2009, a similar deal was signed by British drug maker GlaxoSmithKline with Dr Reddy's Laboratories.
for anti-diabetic
will market and distribute the entire range of Huminsulin brand of Eli Lilly in the country and in Nepal. has signed a deal with market Galvus (Vildagleptin) in the metros. to
USV will manage marketing activities in tier II and III towns in the next phase.
The valuation remains high and they prefer the alliance route than the acquisition one for the time being.
Another key feature of EMs is that consumers primarily pay for most medications from private means, unlike in regulated markets where a large portion is borne by state/insurance players. Coupled with relatively lower incomes, consumers are thus more pricesensitive than in other markets, the study says. Also, the manufacturing cost in India is 35-40 per cent cheaper than that of US or European markets. Through the alliances, apart from India, all the other emerging markets like Australia, Africa, Middle East and Latin America can be tapped.
Diovan (Novartis), Januvia (Merck Sharp & Dohme), Galvus (Novartis) and Crestor (Astra Zeneca).
These are being sold in India at a discount of up to 80% to the global prices.
The number of people suffering from chronic diseases such as cancer, diabetes, neuropsychiatric conditions and cardiovascular disease is set to double in India by 2020.
Thus, change in patient demographics will fuel demand for quality and
Mercks Sparsh:
In 2009, Mercks Indian subsidiary, MSD Pharmaceuticals, launched Sparsh, a multilingual helpline for diabetics on its drugs Januvia and Janumet to provide diet, exercise, and adherence advice.
Pfizer-ITC:
In July 2011, Pfizer collaborated with FMCG major ITC to enhance its product sales in the rural markets. According to the agreement, Pfizer will sell its over-the-counter products through ITC channels in rural areas. Such noble initiatives can be expected to help pharma MNCs further augment their brand awareness in the domestic market and help tap the segments growth potential.
Domestic companies need to transform their business model to play a larger role in global pharma market
The Indian pharma industry has been able to claim a share in the global market by leveraging its strengths and enhancing its regulatory and technical maturity. Formulations manufactured in India constitute 20 per cent of the global generics market by value, and the overall share of Indian manufactured formulations is as high as 46 per cent in the generics segment in the emerging markets. However, with the onset of the patent regime, the traditional reverse engineering capabilities of Indian pharma companies are no longer helpful, as they would not be able to replicate the patented product and launch it in the domestic market. In future, India would be required to leverage its strengths in supply of low cost medicines across the world and invest in newer areas to drive growth.
New Opportunities
for Domestic Companies
Opportunities exist ranging from the low-value added segment, comprising of NDDS ($134 billion opportunity by 2013), Super generics ($135 billion worth of product expiring between 2010 and 2015) and Biosimilars ($115 billion worth of biologics expiring by 2015), to the High value New Chemical Entity (NCE)/New Biopharmaceutical Entity segment. Thus, domestic companies can look forward to pursue all these opportunities and build capabilities to conduct drug discovery and in house development.